# Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure

> **NCT07085728** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Eastern Cooperative Oncology Group** · enrollment: 74 (estimated)

## Conditions studied

- Myeloma Multiple

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Bortezomib (VELCADE)
- **DRUG:** Dexamethasone
- **DRUG:** Daratumumab-hyaluronidase

## Key facts

- **NCT ID:** NCT07085728
- **Lead sponsor:** Eastern Cooperative Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-08-11
- **Primary completion:** 2027-02-01
- **Final completion:** 2027-02-01
- **Target enrollment:** 74 (ESTIMATED)
- **Last updated:** 2026-05-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07085728

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07085728, "Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure". Retrieved via AI Analytics 2026-09-01 from https://api.ai-analytics.org/clinical/NCT07085728. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*